Related Experiment Videos
High-density lipoprotein cholesterol and prognosis after myocardial infarction
Insights
Low high-density lipoprotein (HDL) cholesterol in men recovering from heart attacks is linked to higher mortality. Maintaining adequate HDL cholesterol levels may be crucial for long-term survival after myocardial infarction.
Area of Science:
- Cardiology
- Preventive Medicine
- Lipid Metabolism
Background:
- The Coronary Drug Project investigated lipid-influencing drugs in post-myocardial infarction patients.
- Understanding the prognostic value of baseline lipid profiles is critical for cardiovascular risk assessment.
Purpose of the Study:
- To examine the relationship between baseline high-density lipoprotein (HDL) cholesterol levels and 5-year mortality in men with a history of myocardial infarction.
- To assess the impact of HDL cholesterol on mortality risk in a specific patient cohort.
Main Methods:
- Analysis of baseline serum HDL cholesterol levels in 354 men randomized to the placebo group in the Coronary Drug Project.
- Correlation of baseline HDL cholesterol concentrations with 5-year all-cause mortality rates.
- Statistical adjustment for 40 baseline variables to evaluate the independent effect of HDL cholesterol.
Main Results:
- A statistically significant inverse relationship was observed between baseline HDL cholesterol and 5-year mortality (p = 0.029).
- Mortality was highest (33.0%) in men with HDL cholesterol < 35 mg/dl, compared to 15.9% - 21.8% in those with higher levels.
- This association remained significant after adjusting for 40 baseline variables (p = 0.042).
Conclusions:
- Baseline serum HDL cholesterol levels are a significant predictor of long-term mortality in men with prior myocardial infarction.
- Lower HDL cholesterol levels are associated with an increased risk of death in this population.
- These findings underscore the importance of HDL cholesterol in cardiovascular risk stratification and management.
Abstract:
The Coronary Drug Project was a randomized, placebo-controlled trial of lipid-influencing drugs in men who had recovered from one or more documented myocardial infarctions. Determinations of high-density lipoprotein (HDL) cholesterol were made at baseline in a group of 354 men randomized to the placebo group. Five-year mortality was highest (33.0%) in men with baseline serum HDL cholesterol levels of less than 35 mg/dl; it was 15.9%, 17.7%, and 21.8% in men with levels of 35--39, 40--44, and greater than or equal to 45 mg/dl, respectively (for the linear inverse relationship between HDL cholesterol and 5-year mortality, p = 0.029). Adjustment for 40 baseline variables had a minimal effect on this relationship (p = 0.042).